These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 25294908)

  • 21. Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Satoh Y; Ishii N; Aoki M
    Mol Cancer Ther; 2015 Mar; 14(3):704-12. PubMed ID: 25589496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic FGFR3 gene fusions in bladder cancer.
    Williams SV; Hurst CD; Knowles MA
    Hum Mol Genet; 2013 Feb; 22(4):795-803. PubMed ID: 23175443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A metabolic function of FGFR3-TACC3 gene fusions in cancer.
    Frattini V; Pagnotta SM; Tala ; Fan JJ; Russo MV; Lee SB; Garofano L; Zhang J; Shi P; Lewis G; Sanson H; Frederick V; Castano AM; Cerulo L; Rolland DCM; Mall R; Mokhtari K; Elenitoba-Johnson KSJ; Sanson M; Huang X; Ceccarelli M; Lasorella A; Iavarone A
    Nature; 2018 Jan; 553(7687):222-227. PubMed ID: 29323298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
    Moes-Sosnowska J; Skupinska M; Lechowicz U; Szczepulska-Wojcik E; Skronska P; Rozy A; Stepniewska A; Langfort R; Rudzinski P; Orlowski T; Popiel D; Stanczak A; Wieczorek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration.
    Banella C; Ginevrino M; Catalano G; Fabiani E; Falconi G; Divona M; Curzi P; Panetta P; Voso MT; Noguera NI
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):163-168. PubMed ID: 32199932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
    Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W
    J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
    Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
    Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.
    Cheung HW; Du J; Boehm JS; He F; Weir BA; Wang X; Butaney M; Sequist LV; Luo B; Engelman JA; Root DE; Meyerson M; Golub TR; Jänne PA; Hahn WC
    Cancer Discov; 2011 Dec; 1(7):608-25. PubMed ID: 22586683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a FGFR3-TACC3 fusion in esophageal cancer.
    Mizukami T; Sakai K; Naruki S; Taniyama T; Horie Y; Izawa N; Tsuda T; Fujino T; Boku N; Yasuda H; Fukunaga T; Nakajima TE; Nishio K
    Ann Oncol; 2017 Feb; 28(2):437-438. PubMed ID: 27771611
    [No Abstract]   [Full Text] [Related]  

  • 33. Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling.
    Nelson KN; Meyer AN; Wang CG; Donoghue DJ
    Oncotarget; 2018 Sep; 9(76):34306-34319. PubMed ID: 30344944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate.
    Akbulut O; Lengerli D; Saatci O; Duman E; Seker UOS; Isik A; Akyol A; Caliskan B; Banoglu E; Sahin O
    Mol Cancer Ther; 2020 Jun; 19(6):1243-1254. PubMed ID: 32217742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a degrader against oncogenic fusion protein FGFR3-TACC3.
    Shibata N; Cho N; Koyama H; Naito M
    Bioorg Med Chem Lett; 2022 Mar; 60():128584. PubMed ID: 35085722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGFR3 signaling and function in triple negative breast cancer.
    Chew NJ; Nguyen EV; Su SP; Novy K; Chan HC; Nguyen LK; Luu J; Simpson KJ; Lee RS; Daly RJ
    Cell Commun Signal; 2020 Jan; 18(1):13. PubMed ID: 31987043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
    Izumi H; Matsumoto S; Liu J; Tanaka K; Mori S; Hayashi K; Kumagai S; Shibata Y; Hayashida T; Watanabe K; Fukuhara T; Ikeda T; Yoh K; Kato T; Nishino K; Nakamura A; Nakachi I; Kuyama S; Furuya N; Sakakibara-Konishi J; Okamoto I; Taima K; Ebi N; Daga H; Yamasaki A; Kodani M; Udagawa H; Kirita K; Zenke Y; Nosaki K; Sugiyama E; Sakai T; Nakai T; Ishii G; Niho S; Ohtsu A; Kobayashi SS; Goto K
    Nature; 2021 Dec; 600(7888):319-323. PubMed ID: 34819663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer.
    Dhami J; Hirshfield KM; Ganesan S; Hellmann M; Rojas V; Amorosa JK; Riedlinger GM; Zhong H; Ali SM; Pavlick D; Elvin JA; Rodriguez-Rodriguez L
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29588307
    [No Abstract]   [Full Text] [Related]  

  • 40. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.